Core Viewpoint - The article discusses the advancements and applications of artificial intelligence (AI) in the field of biomanufacturing, highlighting various case studies and innovations presented at the SynBioCon 2025 conference [1][44]. Group 1: AI Empowerment in Biomanufacturing - The conference featured a series of activities promoting typical application cases of AI in biomanufacturing, including forums on AI-driven innovations [1][3]. - Shanghai Zhiyu Biotechnology introduced the "ZCloud Biocomputing Platform" and "ZBot Experimental Verification Platform," achieving the production of vanillin through enzyme methods at a scale of hundreds of tons [6]. - Baidu Biotechnology has emerged as a global leader in foundational models for life sciences, showcasing their xTrimoDNA and xTrimoProtein models and applications [7]. Group 2: Innovative Technologies and Applications - Dibil Biotechnology developed an intelligent dynamic and optimization system for microbial culture, enabling real-time prediction of intracellular metabolic flux [10]. - The roundtable discussion emphasized the importance of technology empowerment, scenario innovation, and ecological collaboration to drive high-quality industrial development [13]. - A high-throughput protein engineering platform was established, leading to the discovery of a new gene editing tool with a 40% efficiency increase and the identification of two new industrial enzymes with over ten times the catalytic activity of competitors [16]. Group 3: Future Food and Agriculture - The conference included discussions on the rapid growth of the global functional sugar market and the challenges in obtaining new functional sugars due to unclear biosynthesis pathways [28]. - The research center of Yili Group focused on developing a self-controlled probiotic R&D technology system tailored to the gut microbiome characteristics of the Chinese population [30]. - The report from Henglu Biotechnology highlighted the development of human milk oligosaccharides and their potential applications, with a focus on safety assessments for production strains [32]. Group 4: Industry Trends and Innovations - The article mentions the establishment of China's first enzymatic production line for vitamin A palmitate by Xinhai Biotechnology, which has entered into strategic cooperation for product development [33]. - The report from Zhejiang University discussed the development and application of biotechnology in fine chemical production [34]. - The potential of microalgae as a sustainable food source was emphasized, showcasing advancements in microalgae protein cultivation and its nutritional benefits [43].

Core Viewpoint - The article highlights the transformative potential of synthetic biology in traditional industries, particularly in agriculture, through a strategic partnership between GELEXIMCO Group, Vietnam National University of Agriculture, and Senrise Biotechnology [1][10]. Group 1: Market Overview - The global synthetic biology market is projected to reach $16 billion by 2024, with an annual growth rate of 27% over the past five years [1]. - Vietnam's agricultural market is substantial, with an estimated total output value of around $50 billion in 2024, showing a rising demand for green agricultural bioproducts [4]. Group 2: Strategic Partnership - The collaboration aims to develop and mass-produce synthetic biological products such as ginsenoside, jasmonate, and astaxanthin, focusing on sustainable agricultural practices [1][4]. - This partnership is expected to enhance cooperation between China and Vietnam in cutting-edge biotechnology, injecting new momentum into the green transformation of agriculture in ASEAN [1][10]. Group 3: Company Profiles - GELEXIMCO Group is a significant player in Vietnam's economy, with annual revenues exceeding 200 trillion VND and total assets reaching 800 trillion VND, aiming to establish a competitive synthetic biology platform [6]. - Vietnam National University of Agriculture is a leading institution in agricultural education and research, providing expertise and local insights for the partnership [7]. - Senrise Biotechnology has developed over 70 patents and utilizes AI algorithms and automated platforms for efficient production, focusing on high-yield chassis cells and precision fermentation [8]. Group 4: Societal Impact - The collaboration is expected to significantly contribute to Vietnam's agricultural green transformation and high-quality development by promoting environmentally friendly agricultural practices [10]. - The project will foster talent development in synthetic biology and modern agriculture, establishing a collaborative innovation platform between academia and industry [10].

Core Viewpoint - Zhejiang Zhenyuan Co., Ltd. reported a significant decline in revenue for the first half of 2025, with total revenue of approximately 1.28 billion yuan, a decrease of 34.49% compared to the same period last year, primarily due to the exclusion of its subsidiary Zhenyuan Medicine from the consolidated financial statements following a capital increase and share expansion [15][21]. Company Overview - Zhejiang Zhenyuan Co., Ltd. operates in the pharmaceutical industry, focusing on pharmaceutical distribution and manufacturing, including traditional Chinese medicine processing and health products [5][8]. - The company has established a strong brand presence, with its flagship store "Zhenyuan Hall" recognized as a time-honored brand in China, contributing to its competitive advantage in the market [20]. Financial Performance - The company reported a net profit attributable to shareholders of approximately 56.26 million yuan, an increase of 29.27% year-on-year, while the net profit after deducting non-recurring gains and losses was about 30.12 million yuan, a decrease of 20.32% [15][21]. - The total assets of the company at the end of the reporting period were approximately 2.96 billion yuan, down 13.55% from the previous year [15]. Business Segments - The pharmaceutical distribution segment includes wholesale and retail operations, with Zhenyuan Medicine successfully attracting strategic investment from China Resources Pharmaceutical Group, enhancing its market competitiveness [8][16]. - The retail segment, led by Zhenyuan Medicine Chain Co., Ltd., has been recognized as a top 100 pharmaceutical chain enterprise in China, with a focus on integrating online and offline services [9][10]. Industry Trends - The pharmaceutical industry is undergoing structural changes, with a shift from price reduction to ensuring supply and quality, driven by national policies aimed at improving healthcare services [6][7]. - The integration of digital tools and online services in the pharmaceutical retail sector is becoming a mainstream trend, enhancing operational efficiency and customer service [6][12]. Research and Development - Zhenyuan Pharmaceutical has a strong focus on R&D, with multiple certifications and patents, and is recognized as a national high-tech enterprise [14][21]. - The company is actively involved in the development of synthetic biology technologies and has established collaborations with leading research institutions to enhance its product offerings [14][21].

工业和信息化部新闻宣传中心主任张学军在发布会上表示，近年来，伴随生物制造领域科技创新的加速 突破、政策体系的逐步完善、产业要素的持续投入，我国生物制造发展跑出"加速度"，原创性研究成果 不断涌现、成果产业化步伐持续加快、代表性行业企业竞相发展，生物制造领域的科技创新对新产业 （300832）、新模式、新动能的催生带动作用显著增强。在此背景下，本次论坛以"生机无限制引未 来"为主题，以"推动生物制造领域科技创新和产业创新融合发展"为宗旨，内容丰富，亮点纷呈：设定 了"1+3+N"的活动架构，包含1场开幕式暨主论坛，3场平行会议，N项特色活动。其中，开幕式暨主论 坛将围绕"科技创新引领现代化产业体系建设"目标，邀请一批顶尖学者和创新企业家分享真知灼见，发 布一批生物制造领域创新发展的最新成果，展示一批行业各方的创新实践和成功经验；平行会议方面， 面向生物制造领域科技创新和产业创新融合发展的三个重点方向，将策划举办合成生物学技术创新会 议、生物制造产业转化促进会议以及新兴技术赋能合成生物学创新会议；特色活动方面，本次论坛将突 出科技创新引领、助力产业宣传普及、展现常德地方产业特色，推出生物制造领域颠覆性创新成果、成 ...

Core Insights - The "2025 Guangzhou Medical and Health Industry Expo" will be held from August 22 to 24 at the China Import and Export Fair Complex, organized by the Guangzhou Municipal Government and relevant health authorities [1] - The expo will cover an exhibition area of 30,000 square meters, featuring 3 pavilions and 18 exhibition areas, showcasing cutting-edge technologies such as gene editing, cell therapy, organoids, organ-on-a-chip, nuclear medicine, 3D printing, biomanufacturing, and synthetic biology [1] - The event aims to encompass the entire industry chain, including R&D, transformation, production, clinical application, third-party services, and financial support [1] Industry Participation - The expo has attracted participation from health administrative departments from various regions including Anhui, Sichuan, Fujian, Chongqing, and Xinjiang [1] - Top research institutions such as Guangzhou laboratories and technology transfer centers from universities, along with over 50 local tertiary hospitals, have been invited to exhibit [1] Corporate Involvement - Notable exhibitors include large pharmaceutical companies like China Resources, Sinopharm, and Guangzhou Pharmaceutical, as well as innovative firms such as BeiGene, CanSino, and Yipin Hong [1] - Telecommunications companies like China Telecom, China Unicom, and China Mobile are also participating in the expo [1]

Core Viewpoint - The article highlights the advancements and innovations in the production and application of hyaluronic acid by Huaxi Biological Technology Co., Ltd., showcasing its transition from a high-cost medical ingredient to a widely used component in various consumer products through technological breakthroughs [1][2][3]. Group 1: Technological Innovations - Huaxi Biological achieved a 90% reduction in production costs of hyaluronic acid through microbial fermentation, breaking international monopolies and enabling industrial-scale production [3]. - The introduction of enzyme cutting technology in 2011 allowed for precise control of molecular weight, leading to the development of products with different functionalities and earning national recognition [3]. - The adoption of synthetic biology technology in 2020 further enhanced production efficiency by three times and enabled zero-carbon production [3][5]. Group 2: Industry Position and Market Demand - Huaxi Biological has established a complete industrial chain from raw material development to end-user applications, positioning itself as a leader in the global hyaluronic acid market [5][7]. - The company has diversified its product offerings across four main business segments: raw materials, pharmaceuticals, skincare products, and functional foods, which collectively support its growth [7]. - The inclusion of sodium hyaluronate in the new food raw material directory by the National Health Commission in 2021 has spurred the development of new products like "Water Muscle Spring" hyaluronic acid drinking water [7]. Group 3: Global Expansion and Brand Development - Huaxi Biological is leveraging its innovative strategies to penetrate international markets, enhancing product competitiveness and brand recognition [7][8]. - The company is not only selling raw materials but also exporting standards and expanding its market presence in regions like Europe, Japan, and the United States [7]. - The growing global demand for health and wellness products, driven by aging populations, is facilitating the expansion of hyaluronic acid applications in everyday life [7][8].

Core Viewpoint - The 2025 China Biomanufacturing Technology Innovation Forum aims to promote the integration of technological and industrial innovation in the biomanufacturing sector, highlighting its potential to lead the Fourth Industrial Revolution and transform traditional manufacturing and agriculture [1][3]. Group 1: Forum Overview - The forum will take place from September 25 in Changde, Hunan, lasting for two days, with the theme "Unlimited Vitality Leads the Future" [1]. - The event is structured around "1+3+N," which includes one opening ceremony and main forum, three parallel sessions, and multiple special activities [3]. Group 2: Key Activities - The main forum will focus on "Technological Innovation Leading the Construction of a Modern Industrial System," featuring top scholars and innovative entrepreneurs sharing insights and showcasing the latest achievements in biomanufacturing [3]. - Parallel sessions will cover three key areas: synthetic biology technology innovation, biomanufacturing industry transformation, and the integration of emerging technologies like AI with biomanufacturing [3]. Group 3: Special Activities - The forum will highlight disruptive innovations in biomanufacturing and share successful case studies, along with a "Biomanufacturing Industry Science Popularization Report" to enhance public understanding [4]. - Special activities will also include showcasing Changde's local industrial capabilities and inviting investment in biomanufacturing [4]. Group 4: Changde's Biomanufacturing Landscape - Changde has a solid foundation in biomanufacturing, with a mature innovation chain and significant policy support, making it a reference point for innovation exploration [5]. - The synthetic biomanufacturing industry in Changde has seen a remarkable growth rate of 23.5% from January to July this year [5]. - A new local regulation to promote the development of the synthetic biomanufacturing industry was approved, marking a significant step in institutionalizing policy benefits [5].

Core Viewpoint - China Petroleum & Chemical Corporation (Sinopec) reported significant declines in performance for the first half of 2025, primarily due to falling international crude oil prices and low chemical market margins [1][2]. Financial Performance - Sinopec achieved revenue of 1.41 trillion yuan, a year-on-year decrease of 10.6% [1] - The net profit attributable to shareholders was 21.483 billion yuan, down 39.8% year-on-year [1] - Basic earnings per share fell to 0.177 yuan, a decline of 40.2% [1] - Operating cash flow increased by 44.4% to 61.016 billion yuan, attributed to reduced working capital needs [1] Debt Situation - The company's debt pressure is significant, with a debt-to-asset ratio of 54.1%, an increase of 0.93 percentage points [1] - Short-term debt rose by 32.7% to 116.472 billion yuan [1] - Long-term debt increased by 8.6% to 203.232 billion yuan [1] - Non-current liabilities due within one year rose by 39.5% to 90.111 billion yuan [1] Segment Performance - The exploration and development segment saw operating income drop by 18.9% to 23.638 billion yuan, despite record domestic oil and gas equivalent production [3] - Oil and gas equivalent production reached 262.81 million barrels, a 2% increase year-on-year [3] - The refining segment experienced the largest decline in operating income, down 50.4% to 3.535 billion yuan [4] - Total refined oil sales volume decreased by 5.8% to 11.214 million tons [4] Chemical Division - The chemical division's operating loss expanded from 3.164 billion yuan to 4.224 billion yuan [4][5] - Sales of major chemical products totaled 231.1 billion yuan, a decrease of 3.2% [5] - Capital expenditure for the first half was 43.8 billion yuan, with a planned reduction of about 5% for the full year [5] Strategic Initiatives - Sinopec plans to accelerate the construction of gas and electric charging networks, transitioning towards a comprehensive energy service provider [7] - The company aims to build at least 500 battery swap stations this year, with a long-term goal of 10,000 stations [7] - Sinopec is collaborating with CATL in various sectors, including battery materials and zero-carbon initiatives [8] - The company has outlined operational plans for the second half of the year, including production targets for crude oil and natural gas [8]

Core Viewpoint - The company, Lushang Freda Pharmaceutical Co., Ltd., reported a decline in revenue and profit for the first half of 2025, primarily due to challenges in the cosmetics and pharmaceutical sectors, including product iteration and pricing pressures from expanded procurement policies [1][2][3]. Company Overview and Financial Indicators - The company reported a total revenue of approximately 1.79 billion yuan for the first half of 2025, a decrease of 7.05% compared to the same period last year [2]. - The total profit for the period was approximately 153 million yuan, down 17.31% year-on-year [2]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was approximately 107.96 million yuan, reflecting a decrease of 15.16% [2]. - The total assets of the company at the end of the reporting period were approximately 6.04 billion yuan, showing a slight increase of 0.61% from the previous year [2]. Industry and Main Business Situation - The company operates in the cosmetics, pharmaceuticals, and raw materials sectors, with a focus on product innovation and market expansion [3][5]. - The domestic cosmetics market has shown signs of slowing growth, with retail sales growth of cosmetics lagging behind overall retail sales growth [3]. - The pharmaceutical sector is facing challenges due to expanded procurement policies and price reductions for winning products, impacting revenue generation [3][5]. Business Performance - The cosmetics segment reported a revenue of approximately 5.54 billion yuan, a year-on-year increase of 23.78%, while the brand "Aier Doctor" saw a significant revenue decline of 29.97% [10][11]. - The company has launched over 80 new products in the cosmetics sector during the reporting period, including key products from various brands [12][13]. - The pharmaceutical segment has been actively developing new products and enhancing brand visibility through participation in industry conferences and events [11][14]. Sales and Marketing Strategies - The company has established a comprehensive online and offline sales network, with online sales accounting for 84.20% of total revenue in the cosmetics segment [11]. - The marketing strategy includes leveraging social media and e-commerce platforms for brand promotion and customer engagement [10][11]. - The company is focusing on enhancing its product offerings and optimizing pricing strategies to improve market competitiveness [10][11]. Research and Development - The company has made significant advancements in research and development, particularly in the field of hyaluronic acid, which is widely used across various industries [3][8]. - The R&D efforts are supported by collaborations with academic institutions and the establishment of technology innovation systems [12][14]. - The company has received multiple certifications for its production facilities, emphasizing its commitment to quality and sustainability [15].

平行会议方面，面向生物制造领域科技创新和产业创新融合发展的三个重点方向，策划举办合成生物学技术创新会议，邀请生 物制造领域专家学者等围绕行业创新趋势热点进行分享交流；策划举办生物制造产业转化促进会议，邀请创新企业家、科技服 务业机构代表等围绕生物制造领域产业成果转化路径、所需平台要素等进行交流对接；策划举办新兴技术赋能合成生物学创新 会议，邀请人工智能、智能制造等领域专家及企业家分享探讨人工智能等新兴技术与生物制造融合发展的新场景、新模式、新 方向。 21世纪经济报道见习记者冉黎黎 北京报道 2025年政府工作报告提出，建立未来产业投入增长机制，培育生物制造等未来产业。8月21日，2025中国生物制造科技创新论坛 新闻发布会召开，发布会上介绍，2025中国生物制造科技创新论坛将于9月25日在湖南常德正式开幕，为期2天，论坛主题为"生 机无限 制引未来"。论坛以"推动生物制造领域科技创新和产业创新融合发展"为宗旨，设定了"1+3+N"的活动架构，包含1场开 幕式暨主论坛，3场平行会议，N项特色活动。 "生物制造是科技创新和产业创新融合发展的重要领域，具备引领第四次工业革命的潜力，将会带来重构传统制造业的生产模 ...